Duration of trastuzumab in HER2-positive metastatic breast cancer after complete remission: still debatable issue?
Crossref DOI link: https://doi.org/10.1007/s10549-017-4536-6
Published Online: 2017-10-11
Published Print: 2018-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Altundag, Kadri http://orcid.org/0000-0003-3357-0096
License valid from 2017-10-11